Treatment Practices in Metastatic Melanoma

Opinion
Video

Allison Betof Warner, MD, PhD, and the Oncology Brothers share clinical insights on treatment decisions for patients with metastatic melanoma.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
Related Content
When is Nivolumab/Relatlimab Therapy Viable in BRAF+ Melanoma?

When is Nivolumab/Relatlimab Therapy Viable in BRAF+ Melanoma?

Ariana Pelosci
September 17th 2025
Article

Clinicians discuss the best treatment options for a 46-year-old woman diagnosed with BRAF+ melanoma.

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

The developer submitted their request in writing and anticipates a response from the FDA before the end of Q3 2025.

FDA Accepts Type C Meeting for Doxorubicin-MNA in Basal Cell Carcinoma of the Skin

Tim Cortese
August 22nd 2025
Article

D-MNA achieved complete clinical clearance in 60% of patients, with no dose-limiting toxicities or serious adverse effects observed in those with basal cell carcinoma of the skin.

On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care

Tim Cortese
August 5th 2025
Article

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

3 Things You Should Know About Managing Advanced Melanoma With Oncolytic Viral Immunotherapies

ONCOLOGY Staff
July 30th 2025
Article

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.